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Abstract
Obesity is a complex, chronic disease that has reached epidemic proportions in the United
States and shows no indication of receding. It is a state of chronic low-grade inflammation that
is initiated by morphological changes in large accumulations of adipose tissue. Leptin is a
pleiotropic hormone secreted by adipose tissue, presenting a possible link between obesity and
inflammation. In this study, we assessed the effect of leptin on bone marrow-derived (BM)
dendritic cells (DC) (BM-DC) function, antigen presenting cells vital for the activation of naïve
T cells. Previous data produced in our laboratory established that the addition of leptin to BMDC causes cytoskeletal rearrangement resulting in an increased number, circumference, and
length of llamelopodia/dendrites. We hypothesized that leptin treatment would therefore lead
to an increased capacity of DC to migrate to, to interact with, and to activate T cells. Leptintreated BM-DC functionality was evaluated in vitro using transwell migration assays in
response to a DC-specific chemokine; by flow cytometry to measure the percentage of BM-DC
and T cell interactions; by confocal microscopy to determine the number of T cells interacting
with individual BM-DC; and by measuring activation of antigen-specific T cells. Treatment
with leptin enhanced all measurements of BM-DC function relative to untreated controls. This
is likely due to the increased surface area (dendrite number and length), which increased DC
ability to diapedese and to interact with T cells, therefore potentiating the extent of the physical
contact between these cells. The data obtained from this study suggest leptin plays an
important role in immunological responses, and may specifically contribute to the proinflammatory state found in obesity.
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Chapter 1: Introduction
1.1

Obesity
Obesity is a medical term for the accumulation of body mass, specifically adipose tissue, at

levels much greater than what has been determined as healthy. The cause of the excess
accumulation is the taking in of more calories than one burns with the unused calories stored
into adipose tissue. There are a number of measurements of obesity, which include waist to hip
circumference ratio, skin thickness test, and the current most widely accepted, body mass
index (BMI). BMI is a calculation based on height and weight that is ranked into six categories
of weight: underweight <18.5, normal 18.5-24.9, overweight 25-29.9, obese 30-34.9, severely
obese 35-39.9, and morbidly obese ≥ 40 (Figure 1).

Figure 1: CDC scale of BMI index from normal to morbidly obese.
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Obesity is widespread in developed nations where high fat, high caloric diets are
prevalent, along with life styles that are far more sedentary than in developing countries [1; 2].
In the United States, obesity has reached epidemic proportions with those in lower income
groups suffering at higher rates [1; 3]. In 2009-2010, 12.5 million children and adolescents
aged 2-19 were obese [4; 5; 6]. The World Health Organization predicts that approximately 2.3
billion adults will be overweight with more than 700 million of the overweight ranking in obese
levels of the BMI scales. Current reports from the CDC estimate 35.7% of adults in the United
States are obese [7]. Early studies sighted genetics and ethnicity as the main factors in high
BMI index scores [8; 9; 10]. Those whom are African American or Hispanic are more prone to
obesity than those of White Caucasian decent. In 2006-2008, African Americans had a 51%
and Hispanics had a 21% higher prevalence of obesity, according to the CDC. Yet, in 2010,
thirty-eight states ranked 25% or more of their populations as obese and thirteen of those
states ranked their populations as over 30% obese (Figure 2).

CDC.gov

Figure 2: CDC map of obesity in the United States in 2010. States with the largest obese
populations are shown in dark orange.
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The effects that obesity can have on the health of the individual can be exceedingly
diverse and the cost of the detrimental health conditions can be extreme. Those who carry the
excessive weight can suffer compounding ailments and diseases such as high blood pressure,
Type 2 Diabetes, as well as heart disease, all connected with metabolic disorders [11] . The
surplus weight can cause sleep apnea, joint problems and lead to arthritis [12]. Those who are
obese are also subject to higher cancer rates, specifically hormone-dependant cancers such as
some breast and prostate cancers [11; 13; 14]. The immune system of an obese person suffers as
well with rates of primary and lethal secondary infections greatly increased [15; 16; 17].

1.2

Adipocytokines
Obesity greatly affects the efficacy of the immune system, cardiovascular system, bones

and joints as well as creates an overall pro-inflammatory environment, which has a detrimental
effect on the comprehensive health of an individual. The internal environment that is created
by abundance in adiposity is the increased production of pro-inflammatory adipo-cytokines
circulating in the periphery causing constant low-grade inflammation [8; 18; 19]. In humans,
this appears to result in poor and dysregulated immunity [17; 20; 21; 22]. Indeed, pathology
shows an increase in macrophage infiltration in obese people potentially due to chronic lowgrade inflammation [17; 23]. Studies in obese mouse models support what has been observed
in humans. Studies that induce obesity in mice by diet, spontaneous mutations, or genetic
engineering display the profound effect that obesity can have on the functionality of the
immune system [24]. In the ob/ob mice, a model created by spontaneous mutation, exposed to
bacterial and viral infections exhibited decreased resistance and increased mortality post
infection [24]. Mice which were given high fat diets to induce obesity have impaired T cell
function during antigen presentation compared to lean control mice [25]. The diet induced
3

obese mice suffered mortality rates seven times higher than lean controls after exposure to the
influenza virus [26]. Thus, the environment created by adipose tissue, due to the production
of endocrine hormones and other products, has a direct and detrimental effect on immunity.

One

of

the

adipocytokines

produced in greater quantity by an obese
person is leptin, a 16Kd, 167 amino acid,
pro-inflammatory

cytokine

pleiotropic

[27].

effects

with

Leptin

is

produced by the OB gene expressed in a
number of different tissues such as the
placenta, stomach epithelium, pituitary,

http://markyoungtrainingsystems.com

Figure 3: The source and general primary function
of leptin.
[28; 29]. Leptin is secreted into the extra cellular matrix and is found in circulation where
ovary, and primarily white adipose tissue

leptin levels can be measured in sera. The original function of leptin was described as the
chemical control of food intake and energy expenditure by acting on the hypothalamus to
signal satiety at the response to food intake (Figure 3) [30]. When exogenous leptin was
administered directly to the brain of the ob/ob mice the result was a reduction in the
consumption of food thereby reducing body weight [31]. However, deficiency of leptin or
resistance to leptin also results in severe obesity as shown in the ob/ob and db/db murine
models [24]. Other functions of leptin include growth control, insulin sensitivity regulation,
reproduction, and immune regulation [32; 33]. The pro-inflammatory nature of leptin is
known to increase T cell activation and increase cytokine production such as Tumor Necrosis
Factor - alpha (TNF-) and Interleukin (IL)– 6 (IL-6) [22; 33]. The activation of T cells and
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production of cytokines in this pro-inflammatory environment with leptin found at increased
levels requires further evaluation, directing speculation to the cells, which are the only APCs
capable of activating naïve T cells.

Leptin has been established as a pro-inflammatory cytokine which assists in the
protection against infection. However, there is evidence of elevated leptin levels and increased
risk of chronic inflammatory disease. Serum leptin levels are found to be elevated in chronic
inflammatory conditions including inflammatory bowel diease, inflammatory nephritis, pelvic
endomertiosis, and Graves’ Disease to name a few [34]. There are many chronic inflammatory
auto-immune disorders that are currently implicating leptin in the role of pathogensis [35].
Type 1 Diabetes and rheumatiod arthritis have shown clinical improvement after 7 days of
fasting intamating a link between leptin and pro-inflammatory disorders [36].

1.3

Thymocytes
Thymocytes or T cells are a type of immune cell in a group of cells identified as white

blood cells, which include B-cells and Natural Killer Cells [37]. They are differentiated by the
existence of T cell receptor (TCR) on the cell surface [38]. These cells originate from
hematopoietic stem cells in bone marrow that inhabit the thymus where they generate a large
population of immature thymocytes [39]. It is in the thymus that they mature where during the
development the cells go through many check points such as positive and negative selection to
avoid immune reactions to self [39]. About 98% of the maturing thymocytes die during the
process by failing this positive or negative selection [40]. The 2% that do survive develop into
T cell subsets with fundamentally different tasks in cell-mediated immunity [41].

5

Many subgroups have been identified with subset within the subsets. Here, a few of the
more prominent subsets will be discussed. Cytotoxic T cells can be termed CD8+ T cells
because of the expression of CD8 glycoprotein on the surface of the cells. The CD8+ T cell
subset recognizes the target cells by binding to antigen presented on cells expressing major
histocompatibility (MHC) class I, which is expressed on every nucleated cell in the body. They
scan for cells infected with intracellular pathogens or virus and destroy them by activating
apoptosis within the infected cell [42]. CD8+ T cells can become activated by cytokines
released from helper T cells or from the direct scanning of infected cells [40].

T-helper cells assist other white blood cells to respond to foreign insults thereby
progressing the immunologic reaction including the maturation of B cells into plasma cells and
memory B cells and the activation of CD8+T cells and macrophages. T-helper cells express CD4
protein on the cell surface. The CD4 protein allows for communication with MHC class II
molecules expressed on the surface of a select few antigen presenting cells (APC) [43]. Once the
CD4+ T cells are activated by the APC, the cells differentiate into several subtypes dependent
on the signaling they have received. One subtype is the T helper-17 cells (Th-17), which produce
IL-17. This subset is thought to play a key role in inflammation and tissue injury common in
autoimmune diseases such as juvenile diabetes, rheumatoid arthritis, and Systemic Lupus
Erythematosus [44].

The activation of CD4+ T cells happens by way of engagement of the T cell receptor
(TCR), in combination with the costimulatory molecule CD28, by class II MHC peptides on the
surface of APC [37]. The recognition of antigen peptide by the TCR induces a signal cascade
that ultimately leads to the expansion of the cell as antigen-specific clones, by proliferation,
accompanied with cytokine production and release by the expanding T cell population.
6

Activated T cells secrete specific cytokines that mediate effecter functions of T cells. This is
followed by the differentiation of some of the progeny into effector cells and memory cells
providing the acquired immunity to the person [40]. The ability of T cells to be activated is
limited to professional antigen presenting cells (APC). The essential antigen-presenting cells
are the highly specialized dendritic cells (DC), whose main function is to present antigen to
naïve T cells and incite an immune response [40].

1.4

Dendritic Cells
Dendritic cells (DC) are a heterogeneous group of bone-marrow (BM) derived cells that

function in immune surveillance, antigen presentation, and tolerance [45; 46; 47]. DCs are
found throughout the body’s periphery constantly scanning the environment and are also
found at the site of infections, recruited by homing chemokines [47; 48; 49]. There are many
different subsets of DC, which are typically defined by their location [50]. Conventional DCs
(cDC) are found in the skin, secondary lymph nodes, and spleens. This population can be subdivided further but as a whole are primarily involved in the initiation of anti-microbial T cellmediated immunity. Plasmacytoid DC (pDC) are located in similar areas but are a significantly
smaller population and express different cell surface markers and different levels of toll-like
receptors making them more selective for virus and fungi. pDC have also been suggested to
play a major role in tolerance induction [51]. Other subpopulations of DC include dermal or
Langerhan DCs, which reside in the skin and express CD207, the cell surface marker specific to
the dermal DC population [52]. Myeloid DC are another subset, which express varying levels of
CD8 and CD4 and are similar to conventional DCs [53]. Splenic DCs are yet another subset of
DCs that are found within the spleen and possess very little migratory ability [45].

7

All populations of DC transition from an immature to mature state. Immature DC are
highly phagocytic; however, once an antigen is ingested and processed for presentation by the
DC, the DC minimizes phagocytic capacity and begins rapid maturation with antigen
presentation to T cells becoming the primary function. Immature DCs expresses the homing
receptor CCR5, which tracks them to site of infections [54]. Upon antigen uptake, CCR5 is
down-regulated and the DC becomes a poor phagocyte [47]. The receptor for the lymph node
homing chemokine MIP-1/CCL19, CCR7, is then up regulated [54]. The DC will then follow a
concentration gradient of CCL19 to the lymph nodes. DC that has acquired antigen processes it
for presentation on both MHC-I and MHC-II allowing them the unique ability to directly
present to CD4+ naïve T cells and cross-present to CD8+ T cells, giving them their unique and
vital role as the communicator between the two branches of the immune system [55]. Naïve T
cells can only be activated by these matured DC making them a pivotal cell in bridging the
innate and adaptive immune systems and is our focal point in investigating the effect leptin can
potentially exert on the immune system.

Preliminary data generated in our laboratory has demonstrated the acute treatment of
bone marrow-derived DC (BM-DC) with obese concentrations of leptin induces drastic
morphological changes in the DC. The BM-DCs were observed to possess an increased number
of dendrites, increased dendrite length, increased dendrite diameter, and increased
lamellapodia formation (coupled with increased concentrations of f-actin at these sites). Based
on this data, I hypothesize that leptin treatment at physiologically high levels as those found in
the morbidly obese (160 ng/ml) in an acute dosage (24-48 hours) leads to an increased
capacity of DC to migrate, to interact with, and activate naive T cells. I surmise that obese
concentrations of leptin may promote DC activation of T cells contributing to inflammation
and dysregulated immunity.
8

Chapter 2: DC Migration
2.1

Abstract

It is known that obesity and poor immune responses are linked. To date, the science
community has not been able to unearth the mechanics of immune dysregulation that results
in deficient immunity. Studies have identified leptin as a pleiotropic adipocytokine that can
alter functionality of immune cells. Produced by white adipose tissue at a concentration
directly proportional to adiposity, leptin is found circulating in very high concentrations in
obese individuals. We have previously found that acute exposure of bone marrow-derived
dendritic cells (BM-DC) to obese concentrations of leptin results in filamentous actin, an
increase in overall surface area, and an increase in the number and diameter of dendrites. We
therefore hypothesize that high concentrations of leptin enhance the migratory ability of DC.
Here we appraised the effects of acute leptin exposure, at levels found in a person with a BMI
of over 35, on BM-DC ability to migrate in vitro and in vivo. We have found that given an acute
exposure to obese concentrations of leptin, DC exhibit an up-regulation of migratory cell
surface receptors, enhanced migration in vitro, and enhanced migration to draining lymph
nodes in vivo. The increased ability of DC to reach T cells could implicate DC as a focal point of
the immune dysregulation in obese people. Alternatively, these findings could also lead to a
potentially potent adjuvant in vaccine development.

9

2.2

Introduction
The effect of exposure to high concentrations of leptin on the physiology of bone

marrow-derived dendritic cells (BM-DC) has yet to be fully illuminated. Leptin levels within
the body are not stable as the production of leptin is increased with food intake and decreased
when the body has not taken in a meal [56]. This creates peaks and valleys in the blood
concentration of leptin [57]. Those who suffer from obesity produce very high levels of leptin
after consuming a meal [33; 56]. With the growing obese population in the US, it is important
to examine the effect that these high level peaks have on the functionality and effectiveness of
the immune system.

Dendritic cells are found in all body tissues where they reside until receiving signals in
the form of cytokines which notify them of the presence of foreign antigen [45]. The DCs
migrate to the site of infection by responding to a number of chemokines release by distressed
or infected cells [58]. The receptor to these chemical signals, CCR5, is highly expressed on
immature DCs allowing for the swift response to infection [59]. Following antigen processing
the DCs rapidly mature as they then migrate to the lymph nodes to interact with and activate
naïve T cells [60]. During the maturation, DCs down regulate CCR5 and up regulate CCR7,
which is the receptor to the ligand CCL19 released by naïve T cells residing in the lymph nodes,
allowing faster travel to the lymph nodes to commence the adaptive immune response [61].
The diapedesis required for the migration in and out of tissue and to the lymph nodes is
dependent on Platelet/endothelial cell adhesion molecule-1 (PECAM/CD31) and Intercellular
adhesion molecule 2 (ICAM-2/CD102) [62; 63; 64].
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Migratory ability of DCs is dependent on cytoskeletal changes promoting movement and
T cell activation [60]. The cytoskeletal changes are reliant upon antigen acquisition of the DCs.
Prior to the uptake of antigen there is minimal if any polarization of F-actin [65]. At the time of
antigen processing, fasin is activated and responsible for the f-actin rearrangement essential to
the DCs ability to migrate [66]. The activation of fasin causes a process which polarizes the factin and positions the migrated DC to properly interact with T cells in the lymph nodes [67].
The purpose of the increase of actin in the cytoskeleton has yet to be fully understood, however
the need for co-stimulatory molecules to activate the T cells, such as MHC class II and ICAM-1,
is well documented.

Preliminary data generated in our laboratory has demonstrated that the acute treatment
of BM-DCs with obese concentrations of leptin induces drastic morphological changes in the
DC. The BM-DCs were observed to possess an increased number of dendrites, increased
dendrite length, increased dendrite diameter, and increased lamellapodia formation (coupled
with increased concentrations of filamentous actin at these sites). Based on this data, we
hypothesized that leptin treatment at physiologically high levels found in the morbidly obese
(160 ng/ml), in an acute dosage would lead to an increased capacity of DCs to migrate to lymph
nodes. Three experimental approaches were utilized to assess DC migration upon acute leptin
exposure: an in vitro transwell migration assay, an in vivo adoptive transfer migratory assay,
and measuring of cell surface expression of homing receptors by flow cytometry. Our current
investigation asserts that given acute leptin treatment alone or in combination with toll-like
receptor (TLR) stimulation, there is enhanced ability of BM-DCs to migrate to T cells.

11

2.3

Materials and Methods:

Mice
Eight - twelve week C57Bl/6 mice were used as the source of expanded DC (Jackson Laboratory,
Sacramento, CA). Animals were kept at 72o Fahrenheit, 50% humidity, and a 12-12 light-dark
cycle. Animals were fed standard pellet chow ad lib. All experiments were conducted in
accordance with University of Texas at El Paso’s Institutional Animal Care and Use Committee
guidelines.
Cell Culture
Bone marrow was isolated from the tibias and femurs of C57Bl/6 mice; red blood cells were lysed
and the remaining cells were cultured in DC complete media (RPMI 1640 medium
supplemented, 10 ng/ml of Granulocyte Macrophage Colony - Stimulating Factor, 10 ng/ml of
Interleukin-4) (8,9).

On day 7, a portion of the culture was activated with 10 µg/ml of

lipopolysaccharide (LPS, Sigma-Aldrich Inc., St. Louis, MO); another portion of the culture was
treated with 160 ng/ml leptin (Lep, PeproTech., Rocky Hill, NJ); another portion was activated
and treated receiving both LPS and leptin; and a fourth and final portion of cells remained
untreated and inactivated (received neither LPS or leptin). On day 8, the cells were enriched
through magnetic bead sorting for the DC selection marker, CD11c (AutoMACS® Pro Separator,
Miltenyi Biotec, Inc. Auburn, CA, USA).
Transwell migration
Treated and enriched BM-DCs were added to the apical chambers of 12-well transwell plates (BD
Bioscience; 8-µM pore size), and complete media with CCL19 (50 ng/ml) was added to the
12

basement chambers. After 8hr incubation, the underside of the apical chamber was washed to
remove any BM-DC still in the process of migrating. The apical chamber was then removed and
the cells in the basement membrane were counted by Trypan blue exclusion.
Expression of Cell Surface Markers Required for Migration
Assessment of the expression levels of cell surface markers CCR5, CCR7, PECAM, and ICAM-2
was performed on the four groups of day 8 BM-DCs as stated above. Staining was conducted as
per manufactures protocols (BD Pharmingen; 559923, 560767, 558738, 557441). After
staining, the cells were fixed with 1% Paraformaldehyde and immediately analyzed by flow
cytometry.

Adoptive Transfer: in vivo migration

Treated and enriched day 8 BM-DC, were stained with Red Fluorescent Cell Linker Kit (SigmaAldrich PKH26GL-1KT) as per manufactures protocol. The cells were then re-suspended at 3 x
106 cells in 50 µl of phosphate buffered saline (PBS) for injection. Cells were subcutaneously
administrated into the hind footpad of C57BL/6 mice ages 8 - 12 weeks. The mice were allowed
to rest post-injection for 24 hr. The popliteal and inguinal lymph nodes were harvested and
brought to single cells suspension. The cells were immediately analyzed by flow cytometry.

Statistical analysis
Data were evaluated by 1 way ANOVA and Tukey’s Post Test (GraphPad Software, San Diego,
CA).
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2.4

Results
To investigate whether acute treatment of DCs with exogenous leptin at obese

concentrations would enhance the migratory ability of BM-DCs in vitro, BM-DC were treated
with 160 ng/ml of leptin, activated with 10 g/ml of LPS, treated with leptin and activated with
LPS, or were held as no treatment controls. Following a 24 hr incubation period, the cells were
enriched using Automacs Pro magnetic bead cell purification system with CD11C+ cells selected.
The Automacs Pro has 90% population purity post enrichment (data not shown). BM-DCs were
seeded into the apical chamber of a transwell system and allowed to migrate for 8 hrs. Figure 4
shows that given an acute dose of leptin at obese levels in combination with TLR activation, there
is an increase in the number of BM-DC that have migrated through the 8 µM pore filter into the
basement chamber of the transwell system

14
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Figure 4: Treatment of BM-DCs with obese concentrations of leptin and LPS
activation enhances migration in-vitro. Day 7 BM-DCs were treated with leptin (160
ng/ml), activated with LPS (10 µg/ml), both leptin-treated and LPS-activated or were remained in
normal media. 24 hrs later, the DC were enriched by magnetic bead sorting. The DCs were seeded
5
at 3.0 x 10 cells in an insert of a transwell system with an 8.0μm filter. The lower chamber
contained the chemokine CCL19 at a concentration of 50ng/ml and the migrated cells were counted
by Trypan Blue Exclusion was measured at the 8 hr time point. This data is presented as the mean ±
SEM of duplicate wells and is one of 11 representative experiments.

The next step was to evaluate how and why there was in increase in BM-DC migratory
ability. BM-DCs require specific cell surface adhesion molecules in order to migrate or diapedese.
Immature BM-DCs highly express CCR5 on the cell surface and upon maturing down-regulate
CCR5 and up regulate CCR7. The CCR5 homing receptor directs DC to peripheral tissue while
CCR7 directs DC to draining lymph nodes. Thus, the expression levels of these two specific
homing receptors were evaluated. BM-DC were treated with the obese levels of leptin and/or
activated with LPS for the acute time period of 24 hours then enriched by magnetic bead sorting
and prepared for flow cytometry. The data in Figure 5 demonstrate that although leptin does not
cause a statistically significant increase in CCR7 expression, it promotes an extremely significant
down-regulation of CCR5.
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Diapedesis between cell junctures is a necessary function of DCs in vivo to access sights of
infection as well as entering the lymphatic vessels traveling to the nearest draining lymph nodes.
PECAM and ICAM-2 are compulsory to this process. Figure 6 displays that given leptin
treatment, PECAM is expressed on a higher percentage of cells than the positive TLR activated
control. With both leptin treatment and TLR activation there is a significant up-regulation of
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ICAM-2 when compared to the untreated controls.

Figure 6: Leptin treatment alters expression of PECAM while leptin
treatment with LPS activation increases ICAM2 on BM-DCs. d7 BM-DCs
were treated with leptin (160 ng/ml), activated with LPS (10 µg/ml), leptin-treated
and LPS-activated or remained untreated for 24 hr at which time the cells were
enriched and stained with FITC-conjugated anti-PECAM (A) or ICAM2 (B)
respectivtly. Percentage of cells expressing the receptor was determined by flow
16
cytometry. This data is presented as the mean
± SEM of duplicate wells and is
representative of 6 experiments. *p<0.05**p<0.0012 n=6

To evaluate whether this up-regulation of molecules used in DC migration translated into
true enhanced ability of the BM-DCs to migrate in-vivo, an adoptive transfer study was
conducted. BM-DC were cultured, enriched, treated, and stained as stated above. On day 8, 3 x
106 BM-DCs were injected into the hind footpad of a C57BL/6 mouse. The mouse was rested over
night to allow migration. The popliteal and inguinal lymph nodes were then harvested, brought to
single cell suspension and then assessed by flow cytometry. Interestingly, treatment with leptin
alone had no effect on BM-DC migration in comparison to the untreated control. However, when
BM-DC were treated with leptin in combination with LPS activation, a very significant
enhancement in the number of BM-DCs had migrated to the inguinal lymph node, in comparison
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Figure 7: In-vivo migration of BM-DCs is enhanced by treatment with leptin. d7
BM-DCs were treated with leptin (160 ng/ml), activated with LPS (10 µg/ml), leptin-treated
and LPS-activated or remained untreated for 24 hr at which time the cells were washed and
injected into the footpad of naïve C57Bl/6 mice. 24 hrs later, draining lymph nodes
(inguinal) were harvested, pooled, and analyzed by flow cytometry. This data is presented
as the mean ± SEM of duplicate wells and is representative of 3 experiments. ***p<0.0001.
n=3
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2.5

Discussion
Leptin treatment in an acute dosage at physiologically relevant levels as those whom are

severely obese along with LPS activation enhances the migratory ability of BM-DCs. In-vitro BMDC migration is increased as seen in figure 4. This in-vitro assay shows the trend of enhanced
migration which was not significant in the difference in migration between treatments yet, a trend
is established. It must be noted that the method of migration in this in vitro assay does not utilize
cell to cell adhesion thereby is not the best model to simulate the cell to cell adhesion which
occurs in-vitro during the migration of the DCs. This displayed trend did, however, show need for
more investigation in this line of questioning as the use of the chemoattractent CCL19 requires the
up regulation of the receptor CCR7 on BM-DCs. The examination of the expression of the
receptors (figure 5) shows that leptin treatment significantly decreases the expression of CCR5
disabling the DCs ability to migrate to the infection site. The treatment of leptin on combination
with the activation of LPS causes an up regulation of CCR7 indicating an increased ability to
respond to the lymph node homing chemical thereby increasing the BM-DCs ability to migrate to
the lymph node. This idea is also supported by measuring the expression of PECAM and ICAM2.
PECAM expression is not significantly increased but enhanced even without the TLR activation of
LPS. The increase in ICAM2 is significant with leptin and LPS activation, however is still
increased by leptin exposure even compared to LPS alone. This is strongly indicative of an
increased ability of the BM-DCs to migrate in vivo. So it was no surprise, yet greatly pleasing, to
see that the hypothesis was supported as figure 7 clearly shows. The exposure of BM-DCs to the
high concentrations of leptin and LPS activation significantly enhances the migration of the BMDCs in vivo. This enhanced migratory ability of the DCs with peptide to display could lead to
trouble and support autoimmune disorders in the way that there could be far more DCs within
the lymph nodes interacting with T cells. If there is a dysregulation in the functioning of the
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immune screening of self-recognizing T cells and increase in the number of DCs presenting
peptides then the autoimmune disorder could be exacerbated.
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Chapter 3: DC Interaction with T Cells
3.1

Abstract

The functionality of the immune system is suspect in an obese person. The underlying causes
of the dysfunction are yet poorly understood. Recent studies have identified leptin as an
adiposcytokine that is produced in white adipose tissue and is found in high concentrations in
obese people. The effect that leptin may be exerting on the immune system has not been
thoroughly examined. Here we appraised the effects of acute leptin exposure, at levels found in
a person with a BMI of over 35, on bone marrow derived dendritic cell ability to interact with
and activate naïve T cells in-vitro and in-vivo. We have shown that given an acute leptin
exposure and TLR activation, the dendritic cells exhibit enhanced ability to interact with a
greater number of T cells and causing a stronger activation response specifically increasing a
pro-inflammatory cytokine production and pushing toward a Th-17 subset response. These
findings support the hypothesis that high concentrations of leptin contribute to the
deregulation of the immune system by affecting the functionality of BM-DCs and thereby
affecting the adaptive immune response to antigen. This dysregulation and heightened proinflammatory response may be supporting autoimmune disorders such as Systemic Lupus
Eurythamatosis.
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3.2

Introduction

The known impact on bone marrow-derived Dendritic Cells (BM-DC) ability to interact
with naïve T cells given high concentration of leptin is limited. Leptin levels within the body are
not stable as the production of leptin is increased with food intake and decreased when the
body has not taken in a meal[56]. This creates peaks and valleys in the blood concentration of
leptin [57]. Those who suffer from obesity produce very high levels of leptin after consuming a
meal [33; 56]. With the growing obese population in the US, it is important to examine the
effect that these high level peaks have on immune system functionality. The purpose of this
study is to examine the interactions between leptin treated BM-DCs and naïve T cells and to
understand if this interaction causes enhanced activation responses. Previous studies in our
laboratory have shown enhanced migration of BM-DCs to draining lymph nodes in-vitro and
in-vivo as well as cytoskeletal rearrangement. Based on this previous study, it is hypothesized
that leptin treatment at physiologically high levels compared to those found in the morbidly
obese (160 ng/ml), in an acute dosage leads to an increased capacity of DCs to interact with
and activate naïve T cells causing a pro-inflammatory response.

Obesity itself induces a pro-inflammatory state due to the large deposits of white
adipose tissue producing inflammatory cytokines such as tumor necrosis factor- alpha, (TNFα) interleukin-6 (IL-6) and IL-1 [41] and leptin . This constant state of low-grade inflammation
may possibly contribute to autoimmune disorders such as inflammatory bowel disease,
psoriasis, and systemic lupus eurithamatosis (SLE) [68; 69]. Increased levels of leptin have
been linked to increased numbers of TH-17 T cell subsets in-vitro [70]. No study has been
conducted linking leptin levels and SLE disease index; however studies showing increases in
serum IL-17 in those with SLE have been recently published [71; 72; 73]. In a cohort study of
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168 women suffering from SLE, 37% of women were ranked as overweight and 25% were obese
[74]. This shows a critical knowledge gap with intuitive links between obesity and autoimmune
disorders which requires investigating. Immune cells expressing leptin receptors like T cells
and dendritic cells may reveal illusive data.

Dendritic cells are found in all body tissues where they reside until receiving signals in
the form of cytokines which notify them of the presence of foreign antigen [45]. DCs migrate to
the sight of infection to phagocytose and process the foreign matter for presentation to naïve T
cell, effectively creating the adaptive immune response to presented antigen. Once the DCs
have interacted with the T cells specific for the antigen presented the T cells kick into action.
There is an enhanced production of cytokines to communicate to other immune cells that there
is a need for defensive action. Measuring the cytokine production post DC – T cell interacts can
give insight to T cell activation and also allow us to know what kind of defensive response is
cued. T cells will also proliferate in order to increase the number of cells responding to the
antigen of interest. Measuring the proliferation of the antigen presented T cells gives insight
into the immune response which is occurring. Here we measure both occurrences. Interaction
was measured by three methods and activation by two methods. Light microscopy allowed for
the visualization of the BM-DC interaction, followed by flow cytometry for semi-quantification,
then more accurately quantified by high content analysis. Activation of immune cells and
immune response was conducted by industry standards of cytokine measurement through
Enzyme-linked Immuno-sorbent Assay (ELISA) and tritated thymidine (3H) to measure T cell
proliferation. The present study establishes that given acute leptin treatment and TLR
stimulation there is enhanced ability of BM-DCs to interact with and activate naïve T cells.
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3.3

Materials and Methods

Mice
Eight - 12 week C57Bl/6 and OT-II T cell receptor (TCR) transgenic mice were used as the source
of expanded DC and antigen-specific T cells (Jackson Laboratory, Sacramento, CA). Animals
were kept at 72o Fahrenheit, 50% humidity, and 12-12 light-dark cycle. Animals were fed
standard pellet chow ad lib. All experiments were conducted in accordance with University of
Texas at El Paso’s Institutional Animal Care and Use Committee guidelines.
Cell Culture
Bone marrow was isolated from the tibias and femurs of C57Bl/6 mice; red blood cells were lysed
and the remaining cells were cultured in DC complete media (RPMI 1640 medium
supplemented, 10ng/ml of Granulocyte Macrophage Colony - Stimulating Factor, 10 ng/ml of
Interleukin-4) (8,9).

On day 7, a portion of the culture was activated with 10 µg/ml of

lipopolysaccharide (LPS, Sigma-Aldrich Inc., St. Louis, MO) another portion of the culture was
treated with 160 ng/ml leptin (Lep, PeproTech., Rocky Hill, NJ) another portion receiving both
LPS activation and Lep treatment (L + L), leptin, LPS activated, L + L , and a control were
pulsed chicken ovalbumin 323-339 (OVA, Invitrogen C1311) and a portion remained untreated,
inactivated, and not OVA pulsed. On day 8, the cells were enriched through magnetic bead
sorting for CD11c (AutoMACS® Pro Separator, Miltenyi Biotec, Inc. Auburn, CA, USA).
CD-4+ T cells were harvested from the lymph nodes and spleens of OT-II T cell receptor (TCR)
transgenic mice on the day of the experiment. The lymph nodes and spleens were pooled and
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enriched using anti-CD-4 magnetic beads with an enriched purity level of greater than 85%
(AutoMACS® Pro Separator, Miltenyi Biotec, Inc. Auburn, CA, USA).
Light Microscopy
Bright field microscopy was utilized to view interaction between BM-DCs and T cells. Coincubation occurs in a chambered slide at a 1: 10 DC to T cell ratio, with a time course of photos
taken by use of Leica DMIL, McBain Instruments, (Chatsworth, CA) with use of Las EZ image
processing software (Buffalo Grove, IL). Visualization of BM-DC – T cell interaction via light
microscopy in a time course starting at 0 hours, 30 minutes, 1 hour and 12 hours is shown below.
BM-DCs were treated with leptin at 160 ng/ml, activated with LPS at 10 µg/ml (positive control),
both treated and activated or neither treated nor activated (negative control).
Flow Cytometry
Beckman Coulter FC 500 System was employed for the evaluation of the interaction between
leptin-treated, LPS-activated, leptin-treated + LPS-activated, and untreated BM-DCs. BM-DCs
were stained with Red Fluorescent Linker (Sigma PKH26GL) and pulsed with chicken ovalumin
323-339 (Invitrogen C1311) 24 hours prior to co-incubation with T cells. Enriched primary T cell
populations were stained with carboxyfluorescein diacetate, succinimidyl ester (CFSE)
(Invitrogen C34554). The cells were then co-cultured at ratio of 1:5 BM-DCs to T cells in a 96well U-bottom plate for 8 hours.

The reaction was then stopped with the addition 2%

paraformaldehyde (PFA). The samples were then analyzed by flow-cytometry. The cells which
were interacting were fixed together upon addition of paraformaldehyde and will remain
covalently linked together and was quantified by the flow cytometer as a unit of interacting cells
expressing both red (BM-DCs) and green (T cells).
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High Content Analysis
DCs were stained with CellMask™ Deep Red per manufacturer’s protocol (Invitrogen, NY, USA
C10046; 649 /666) and were then pulsed with ovalbumin. CD4+ T cells harvest as stated above
were stained with carboxyfluorescein diacetate, succinimidyl ester (CFSE) per manufacturer’s
protocol (Invitrogen, C34554; 492/517). BM- DCs were co-cultured with enriched green-labeled
T cells at an optimized ratio of 1:10 for a total of 3.2x104 cells/well in 96-well instrument specific
plates (BD Falcon New Jersey, NJ, USA, 353219). Image acquisition and data analysis were
performed with the BD Pathway 855 Bioimager and associated AttoVision v1.6.2 software (BD
Biosciences). 9 images for a 3x3 montage or 25 images for a 5x5 montage were acquired from
each well using a 20/ NA 0.75 dry objective, pre-determined filters sets: 635 / 668 for red
channel and 488 / 515 for green channel. Activated DCs are about 5 times bigger than T cells
[75]; therefore our segmentation approach consisted in defining dendritic cells as red dots equal
or greater than 50 pixels; whereas T cells were defined as green dots equal or greater than 10
pixels. In order to define a ROI, each red dot’s boundaries were artificially enlarged in an
elliptical shape (25x25 pixels) in order to include the surrounding green dots. In this way each
DC became an “object” and T cells located in the proximity “sub-objects”. A ROI defined by one
object (DC) and two or more sub-objects (T cells).The read-out consisted of the number of
objects and their respective count of sub-objects per well. SAS 9.2. software was applied to run
the two-independent samples t-test comparing two means with unequal variances for the
number of clusters in a well (resting DC versus activated DC).
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Proliferation
Co-culture of treated and pulsed BM-DCs and T cells were incubated at a 1 to 5 ratio in a 96 well
flat bottom plate for 72 hours before the addition of the 3H thymidine at 1 µCi per well. 24 hours
were allowed for the incorporation of the 3H. The cells were then harvested on glass fiber paper
(FilterMat 11731, Skatron Instruments Sterling, VA) using an automatic cell harvester (Micro96
Harvester, Saktron Instruments, Sterling, VA). The radioactivity which has been incorporated in
the DNA was measured by liquid scintillation using the LS5801 Beckman Coulter, Fullerton, CA.
ELISA
The measurement of cytokine production is a method of measuring T cell activation.
Supernatants from co-cultures of treated, activated and peptide pulsed BM-DCs and T cells at a 1
to 5 ratio following 48 – 72 hrs of incubation in a 96 well flat bottom plate were collected and
used in this assay. Pro-inflammatory cytokines produced by activated T cells in response to
infection are Interferon gamma (IFNγ), and Interleukin 17 (IL17) were selected and screened for
to show T cell activation using commercially available ELISA kits (Biolegend IFN-γ #430808 IL17#432508) [76; 77; 78].
In-vivo Interaction
Treated, activated, and peptide pulsed BM-DCs were stained with Red Fluorescent Linker and
injected into the footpad of an OTII mouse, at the concentration of 3x106 cells in 50 µl of PBS,
then allowed to migrate into popliteal and inguinal lymph nodes overnight. Lymph nodes were
harvested and cells were stained with anti-CD4-FITC (Biolegend 100509) labeled antibodies to
allow for readings of interaction of the red labeled BM-DCs with green labeled T cell. Cells were
fixed with PFA and evaluated by flow cytometry (Beckman Coulter FC 500 System). The cells
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which were interacting remained covalently linked together and were quantified by the flow
cytometer as a unit of interacting cells expressing both red (BM-DCs) and green (T cells).

Statistical analysis

Data were evaluated by 1 way ANOVA and Tukey’s Post Test (GraphPad Software, San Diego,
CA) A p values vary and are stated in the results.

3.4

RESULTS

To investigate whether acute treatment of DCs with exogenous leptin at levels of the
severely obese would enhance the interaction and thereby the activation of naïve T cells, BM-DCs
were treated with 160 ng/ml of Leptin, activated with LPS, both treated with leptin and activated
with LPS, peptide pulsed alone or combined with all other treatments, or held for no treatment
control for 24 hours. Following the treatments, the cells were enriched using Automacs Pro
magnetic bead cell purification system with CD11C+ cells selected and enriched. T cells were
harvested from the lymph nodes of OTII mice then enriched using Automacs Pro magnetic bead
cell purification system with CD4+ cells positively selected. The Automacs Pro has 90%
population purity post enrichment.

The light microscopy time course assay shows the ability of the visualization of the
interaction of DCs and T cells. The size difference of the two cells is apparent as well as the close
proximity of the DCs and T cells demonstrating interaction of the cells. The time course exhibited
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the limited interaction of DCs and T cells making clear the necessity of the selection of a time
point that is a sampling of the interaction of the cells. Co-cultures were seeded at a 1:5 DC: T cell
ratio and monitored at select time points as seen in the light microscopy time course images
(figure 8 panels A-D). DC-T cell interaction can clearly be viewed in the co-culture as early as
time point 0 as seen in figure 8, B1, C1, and D1 of the LPS, LEP, and L + L treatment with
interactions continuing into the 12th hour as seen in figures C4 and D4 of the same treatment sets.
This assay allowed us to view the interactions but not to assess the interaction in a manner that
would allow for quantification. The next step was to evaluate the interaction a more quantative
method, Flow cytometry.
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Figure 8: Light Microscopy time course displays BM-DC T cell interaction. d7 BM-DCs were treated with
leptin (160ng/ml), activated with LPS (10 µg/ml) both treated and activated or remained untreated for 24 hr at which
time the cells were enriched and co-cultured at 1:5. Red boxes on all images display a large DC with visible dendrites
interacting with a T cell or displaying the DC alone. Time course time points for all treatments are shows as: 1) Time
Point 0 2) Time Point 30 minutes 3) Time Point 1 hr 4) Time point 12 hrs. Panel A: untreated negative control B: LPS
or positive control C: Lep treatment alone and D: Lep + LPS. These images are representative of 3 experiments.

The interaction of the DCs and T cells was measured in a semi-quantitive method as stated
in the materials and methods then assessed via flow cytometery. Figure 9 quadrant II shows
cells which were interacting as a unit expressing both red (BM-DCs) and green (T cells)
fluorescence. DCs not interacting are seen in quadrant I expressing only red and T cells not
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interacting in quadrant II expressing only green. There is a significant enhancement in the
interaction of DCs and T cells given treatment of exogenous leptin at obese levels in an acute
dose and LPS activation in comparison to leptin treatment alone. The treatment of both leptin
and LPS also slightly enhances interaction of the DCs and T cells in comparison to just LPS
activation. Given this insight, a more in-depth study was warranted with a method that could
more accurately quantify the interaction, High Content Analysis (HCA).

HCA allows for the quantification of the interaction of DCs and T cells in a live cell
setting by staining the DCs with Red Florescent Linker and the T cells with CFSE then coculturing at a 1:10 ratio seeding no more than 3.2 x 104 cells per well. Figure 10 displays the
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software’s definition of a region of interest (ROI) defined by the content on one cell expressing
red fluorescence, a DC. T cells express green fluorescence and are counted as sub-objects
(figure 10 A). Figure 10 B shows the area defined around the DC as DCs are amorphous and
dendrites stretch out from the cell body. Areas 1-4 identify DCs in the images and the software
has given each a number corresponding to the ROI number assigned to each defined BM-DC.
Individual T cells are defined by the expressing of green, but in order to insure that each T cell
is individually defined figure 10 C shows each defined T cell in a different color giving an
accurate T cell count as sub-objects. Figure 10 D show the combination of all of this
information which quantifies the single BM-DCs interaction with a count of the T cells
interacting with it. Table 1 gives a summary of the ROIs displayed and the counted sub-object
or, the count of BM-DCs and the number of T cells interacting with them.
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2

Figure 10: HCA of BM-DC interaction with T cells. d7 BM-DCs were treated with leptin (160ng/ml),
activated with LPS (10 µg/ml) ), both leptin-treated and LPS-activated, peptide pulsed, or were remained in normal
media. 24 hrs later, the DC were enriched by magnetic bead sorting co-cultured at 1:5. (A): Pseudo-colored,
merged image (20X) of LPS-activated BM-DC and T cells. DC are red (Cell Mask Deep Red) and T cells are green
(CFSE). (B): Segmentation mask of the same image generated after sub-object analysis depicting DC’s enlarged
boundaries (white line) and numbered cellular ROIs (additionally labeled as numbered ovals for easier
identification). (C): Segmentation mask of the same image depicting T cells as individual sub-objects with
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multiple colors to identify individual T cells and BM-DCs not shown. (D): Segmentation mask of the same image
generated after sub-object analysis depicting enlarged DC in blue (objects) whose boundaries were expanded in
order to include the interacting T cells (sub-objects); T cells are shown in red. Oval 1: DC – T cell cluster with five
interacting T cells; Oval 2 and 4: DC alone with no interacting T cells; Oval 3: DC – T cell cluster with three
interacting T cells. These images are representative of the images gathered by the BD Bioimager for HCA.

Table 1: Summery of the Regions of Interest (ROIs) defined by the DB Bioimager
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DC

T cells

1
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1
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2
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A time course was conducted to identify the ideal time for the
analysis of the interaction. For 24 hours images were acquired
at 4 hour intervals and interaction was assessed (figure 11 A).
The 8th hour of interaction was selected as the best
representation of overall interaction do to the plateauing of the

LPS and LEP treatments and a stalling in the interaction of the L + L treatments as seen in
figure 11 B. Figure 11 C displays the percent of interaction by treatment at the 8 hour time
point with an increase in the interaction of the DCs with the T cells given TLR activation and
LEP treatment. Further experimentation and analysis was conducted after 8 hours of coincubation here on out.
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Figure 11: Leptin treatment enhances DC T
cell interaction. d7 BM-DCs were treated with
leptin (160 ng/ml), activated with LPS (10 µg/ml),

C

both leptin-treated and LPS-activated, peptide
pulsed, or were remained in normal media. 24 hrs
later, the DC were enriched by magnetic bead
sorting. 24 hr time course was conducted with
images taken every 4 hr (A). Time course by
treatment (B). Leptin treated DCs interact with T
cells at a higher rate at 8 hours co-incubation (C).
Interactions were quantified by BD Imager and
graphed as the percent of DCs interacting with one
or more T cells. This data is presented as the mean
± SEM of 6 replicate wells.
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Figure 12: Leptin Treatment and TLR Stimulation Enhances the Number of ROIs and the
number of interacting T cells Compared to TLR Activation Alone. d7 BM-DCs were treated with leptin
(160 ng/ml), activated with LPS (10 µg/ml), both leptin-treated and LPS-activated, peptide pulsed, or were
remained in normal media. 24 hrs later, the DC were enriched by magnetic bead sorting. (A) Significant
increase in the number of ROIs found when BM-DCs are treated with LEP and LPS activated. (B) Leptin
Treatment with LEP Increases the area of the ROIs. (C) ROIs containing one BM-DC interacting with at least 4
T cells. (D) ROIs containing one BM-DC Interacting with at least 5 T cells. This data is presented as the mean ±
SEM of duplicate wells and is one of 5 representative experiments **p<0.01 *p<0.05.

Figure 12 shows that there is a significant increase in the interaction of the BM-DCs
given L + L treatment compared to the LPS control. The LEP treatment causes an increase in
the area of the BM-DCs in comparison to LPS (figure 12 B). This increased surface area was
also seen in previous work and when further analysis was conducted by applying constraints to
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the software defining an ROI by the content of one BM-DC (red) and increased number of T
cells (green) we can plainly see that given treatment with LEP and TLR activation a single BMDC is able to communicate with more T cell at one time as seen in figure 12 C and 12 D where
graphed is the interaction of BM-DCs with a minimum of 4 T cells (figure 12 C) and then
further on showing difference still with one BM-DC communicating with a minimum of 5 T
cells (figure 12 D).

Figure

13:

Stimulation
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Treatment
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and
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TLR

activation

Compared to TLR Activation Alone. d7 BM-DCs
were treated with leptin (160 ng/ml), activated with
LPS (10 µg/ml), both leptin-treated and LPS-activated,
peptide pulsed, or were remained in normal media. 24
hrs later, the DC were enriched by magnetic bead
sorting. (A) Leptin treatment and TLR Stimulation
Enhances T cell Proliferation. (B) Leptin treatment
and LPS activation causes an increase in the
production of IFN- γ and IL-17 (C). This data is
presented as the mean ± SEM of duplicate wells and is
one

of

*p<0.05.
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6
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experiments

**p<0.01

The measured increase in the interaction of a BM-DC with T cells given leptin treatment
and TLR activation lead to the next line of questioning; does the interaction of the cells lead to
a greater immune response of the T cells? T cell activation was measured by proliferation and
cytokine production. Tritated thymidine was used to measure T cell proliferation given 72
hours of co-culture with treated BM-DCs. Figure 13 A shows that both leptin treatment alone
and leptin treatment with TLR activation caused a significant increase in T cell proliferation
compared to the LPS control. The measurement of the production cytokine IFN-γ showed an
increase within the co-culture given leptin treatment and TLR activation (figure 13 B). IL -23
was also measured but showed no difference in production (graph not shown) however, there
was a significant increase in the production of pro-inflammatory cytokine IL-17 (figure 13 C).

With the previous study showing that BM-DCs treated with Leptin and TLR activated
migrated at a faster rate to draining lymph nodes in-vivo, and the data showing stronger
interaction of the same treatment set in-vitro, the next logical step is to assess the interaction
of the treated and activated BM-DC in-vivo as well. This inquiry can be approached by
adoptively transferring stained BM-DCs in to an OTII mouse and allowing over night
incubation then harvesting the draining lymph nodes and staining the T cells with anti-CD4
FITC as stated in materials and methods. Figure 14 presents the data acquired. There is a
significant enhancement of interaction between leptin treated and TLR activated BM-DCs and
CD4 T cells in-vivo.
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Figure 14: In-vivo BM-DC T cell interaction is enhanced by treatment with leptin and
LPS activation. d7 BM-DCs were treated with leptin (160 ng/ml), peptide pulsed, activated with
LPS (10 µg/ml), leptin-treated and LPS-activated or remained untreated for 24 hr at which time
the cells were washed and injected into the footpad of naïve OTII mice. 24 hrs later, draining
lymph nodes (inguinal) were harvested, pooled, and analyzed by flow cytometry. This data is
presented as the mean ± SEM of duplicate wells and is representative of 3 experiments.
****p<0.001

3.5

DISCUSSION
The addition of exogenous leptin to BM-DCs in an acute dose at philologically relevant

levels as those who are severely obese enhance interaction of the BM-DCs with T cells a leading
to enhanced activation and cytokine production. The use of light microscopy allowed the
viewing of the interaction and highlighted the need for more quantitative endeavors and well as
42

a selected representative time point. Interaction is increased by leptin treatment and LPS
activation as seen by flow cytometry in figure 9. However, is the HCA that gives us clear view
into the increase in the interaction do the BM-DCs which have been exposed to the high
concentrations of leptin and activated with LPS. After an acute exposure to the leptin and LPS
activation, the BM-DCs are interacting with more T cells than their untreated counterparts.
This interaction with naïve T cells continues to increase over time while other treatment sets
have leveled off. This indicates that the peaks in leptin levels after in taking a meal have a
potent lasting affect on the BM-DCs and thereby the immune system as a whole. The increased
proliferation of T cells after interacting with BM-DCs exposed to leptin as well as the increase
in the production of IFN-γ and IL-17 indicated that the response of the T cells to the DCs is
inflammatory. The Il-17 in itself is worrisome as Il-17 is strongly associated with autoimmune
disorders. The interaction of the BM-DCs is enhanced in-vivo as shown in figure 14. All the
interaction data taken as a whole shows that the hypothesis of leptin supporting enhanced
interaction with naïve T cell is supported.
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Chapter 4: Extended Discussion

4.1

Discussion and Future Direction

Leptin is found at elevated levels in those whom are obese [79; 80; 81].

As a

consequence of these elevated levels, leptin has been linked to many pro-inflammatory issues
such as ulcerative colitis, arthrosclerosis, and rheumatic diseases to name a few [82; 83; 84].
Based on my data, it is shown that leptin treatment at physiologically high levels compared to
those found in the morbidly obese (160 ng/ml), in an acute dosage leads to an increased
capacity of BM-DCs to migrate to lymph nodes. The modification of the BM-DCs that
contributes to the increased capacity to migrate causes an increased capacity of DCs to interact
with and activate naïve T cells causing a pro-inflammatory response.
As seen in Chapter 2, leptin treatment and LPS activation enhance in-vitro migration
compared to LPS alone. The CCR7 is expressed on slightly more cells treated with leptin and
LPS activated compared to LPS control. This indicates that the leptin treatment changes the
expression of the receptor pushing maturation and increasing the ability of the BM-DC to
travel in-vivo to the lymph node. The reduction in the number of cells expressing CCR5
indicates that these leptin treated cells may not respond to calls to travel to the site of infection
as readily as the DCs not exposed to the high concentrations of leptin. However, there is the
enhanced expression of cellular adhesion molecules PECAM and ICAM 2 (figure 6). This
increased expression was put to use in-vivo where the migration of adoptively transferred BMDCs migrated to draining lymph nodes at a faster rate given leptin treatment and LPS
activation PECAM and ICAM2 are essential adhesion molecules in diapedesis and cellular
migration [62; 63; 64]. Therefore the increased expression on the BM-DCs given leptin
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treatment along with LPS activation indicates that leptin exposure does augment the BM-DCs
migratory ability. This is shown as true in the adoptive transfer study of the treated and
activated BM-DCs where it is seen that the treatment and activated population is found in
greater numbers in the inguinal lymph nodes compared to controls (figure 7). The logical
subsequent inquiry becomes, “what are the BM-DCs doing now that they are there in the lymph
nodes?”

The interactions between BM-DCs and T cells can be observed by use of a light
microscope (also called bright field) as the two cell types differ in size and morphology. In this
investigation we discern that time points of the observations matter. A short time course was
conducted to illustrate this point. This survey afforded us the ability to see the difference in the
interaction between the treatments of the BM-DCs. Notwithstanding the viewed differences in
the treatments, the assay was not quantitative. Flow cytometry shows a semi-quantitative
result of increased interaction between the BM-DCs and T cells with a significant increase in
interacting cells given leptin treatment and LPS activation.

High Content Analysis (HCA) shows the best time for quantification to be at 8 hours yet
we also see that though the interaction with cells with no ova peptide added level off at 12
hours, the peptide loaded cell interaction levels off at 8 hours, the LPS treated cell interaction
levels off at 8 hours, the lep treated cells level off at 8 hours, the LPS and lep treated cells
interaction levels stall at 8-12 hour time points but then continue to increase all through the 24
hour time course. Thus, the 8 hour time point was selected as the best representative time
point for interaction of naïve T cells and BM-DCs. Investigating this interaction further at 8hrs,
we see that the number of ROIs found is significantly higher in the LPS activated and leptin
treated group shown in figure 10 C compared to LPS activated group. This is evidence that
45

with the activation and treatment there are more groups of BM-DCs interacting with more
groups of T cells. The intensity of the ROIs is also significantly increased given leptin treatment
and LPS activation (figure 10 B). This may be caused by actin rearrangement effected by leptin
making the BM-DCs larger and of a greater meter as seen in preliminary studies in the Garza
laboratory. This bulking up of the BM-DCs plays a part in the ability of the DC to interact with
more naïve T cells as seen in figure 10 C. With leptin treatment the single BM-CD interact with
more T cells at a one time. Therefore leptin treatment along with LPS activation enhances the
ability of BM-DCs to interact with naïve T cells enabling the BM-DCs to communicate with
more T cells at one time as well as enabling more T cell interaction with a BM-DC in general.

With the increase interaction occurring, there is more T cell activation as measured by T
cell proliferation and cytokine production. Figure 13 A displays that given leptin treatment
alone as well as leptin treatment and LPS activation T cells proliferate at significantly higher
rates showing T cell activation hence more BM-DC – T cell interaction. The T cells produce
more IFN-γ with leptin treatment and LPS activation showing enhanced T cell activation with
pro-inflammatory cytokine production as seen as well in the significantly increased production
of IL-17 (figure 13 B-C). This is particularly interesting in that IL-17 production pushes for a
TH-17 subset. This subset is found at very high levels in those suffering from autoimmune
disorders such as systemic lupus eurthramatosis.

It is revealed that leptin has an effect in the functionality of BM-DCs in the ability to
migrate and in the interaction with T cells. This effect can have an array of outcomes
depending on the environment in which the DCs are exposed as well as the environment in
which they are to function. If the DCs are in the body of an obese person, then we can view this
acute dosage study as what effect the after-meal-intake leptin peaks are having on DCs
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previously unexposed to the high concentrations of leptin. This exposure has lingering effects
on the DC functionality. This effect is exacerbated if there is antigen present in the body and
the DCs are exposed to them. This can lead to dysfunction in the ability of DCs to respond to
directional signals from t cells. Enhanced ability of the DCs to migrate to lymph nodes which
causes activation of T cells in a manner that intensifies a pro-inflammatory immune response
in a negative feedback loop. This can contribute to the immune system dysfunction of one who
is obese. Future studies of this lineage should include signaling of cytoskeleton rearrangement
like that of ROC/RHO. Studies utilizing Diet Induced Obesity models of infection clearance
and histological studies after adoptive transfers should also be conducted. The chronic
presence of leptin in the systems of those who are obese presence yet another facet to the
possible future studies as this study conducted was solely on the acute exposure of BM-DCs.

Studies as to the causes and longevity of inflammatory disorders have been conducted
for decades, yet there are critical knowledge gaps in understanding and thus treating disorders
such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE). This current
study opens another avenue of interests focusing on leptin’s pro-inflammatory influence on the
immune system and the possible influence this may have on such disorders. There are a large
percentage of women who suffer from SLE that are obese and obesity is a known risk factor for
RA [85; 86]. The augmentation of the function of BM-DCs caused by leptin could be
contributing greatly to the inflammatory TH17 subset found in high numbers in SLE patients
[76; 87]. Based on my data presenting leptin’s ability to cause a significant increase of IL-17,
future studies should be conducted with a strong focus on leptin and inflammation, TH17
populations and indices in mouse models such as NZBF-J1 commonly use to study SLE as well
as inducing obesity in the models. This has potential therapeutic significance which is badly
needed in these diseases.
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Another course which this study has illuminated is the possibility of leptin as an
adjuvant. Aluminum gels and salts are currently the only adjuvants allowed to be used in the
United States [88]. That knowledge in itself makes the potential for a new adjuvant exciting.
Leptin’s effect on dendritic cells should be studied alongside of the development of dendritic
cell vaccines as a potential support component. Leptin could buttress the strength of the DC
vaccination by affecting a stronger immune response. Naturally, this will have to be examined
in combination with chronic leptin exposure as in the systems of obese individuals.

In conclusion, the addition of exogenous leptin in obese concentrations in an acute
dosage has proven to enhance the ability of bone marrow – derived dendritic cells to migrate
in-vivo to draining lymph nodes, interact with naïve T cells, and cause a pro-inflammatory
immune response. This knowledge gives sagacity as to the effect leptin can exert on immune
function given leptin peaks post meal intake. The research opens many potential courses of
study which could lead to therapeutic applications and preventative potential usages.
Understanding the full effect of leptin is essential in order to establish both detrimental and
beneficial attributes of this pleiotropic adipocytokine.
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